Outcomes by IPSS-R in lenalidomide-treated patients with IPSS low-/Int-1-risk MDSWith del(5q) in MDS-003 and MDS-004: A retrospective analysis

被引：3
|
作者：
Sekeres, M. [1 ]
Swern, A. [2 ]
Fenaux, P. [3 ]
Greenberg, P. [4 ]
Sanz, G. [5 ]
Bennett, J. [6 ]
Dreyfus, F. [7 ]
Cazzola, M. [8 ,9 ]
List, A. [10 ]
Garcia-Manero, G. [11 ]
Li, J. Shiansong [2 ]
Sugrue, M. [12 ]
机构：
[1] Cleveland Clin, Taussig Canc Inst, Leukemia Program, Cleveland, OH 44106 USA
[2] Celgene Corp, Biostat, Summit, NJ USA
[3] Avicenne Hosp, Dept Clin Hematol, Bobigny, France
[4] Stanford Univ, Div Hematol, Stanford, CA 94305 USA
[5] Hosp Univ & Politecn La Fe Valencia, Dept Hematol, Valencia, Spain
[6] Univ Rochester, Div Hematopathol & Hematol Oncol, Med Ctr, Rochester, NY 14627 USA
[7] Univ Paris, Hop Cochin, Dept Hematol, F-75252 Paris, France
[8] Fdn IRCCS Policlin San Matteo, Dept Hematol Oncol, Pavia, Italy
[9] Univ Pavia, I-27100 Pavia, Italy
[10] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Dept Hematol Malignancies, Tampa, FL 33612 USA
[11] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA
[12] Celgene Corp, Med Affairs, Summit, NJ USA
来源：
LEUKEMIA RESEARCH | 2013年 / 37卷
关键词：
D O I：
10.1016/S0145-2126(13)70152-8
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P-104
引用
收藏
页码：S69 / S70
页数：2
相关论文
共 50 条
  • [41] Karyotype evolution in patients with MDS and isolated deletion (5q) with IPSS low or intermediate-1-risk: Results of LeMon5 study
    Shirneshan, K.
    Platzbecker, U.
    Nolte, F.
    Giagounidis, A.
    Goetze, K.
    Braulke, F.
    Schanz, J.
    Germing, U.
    Haase, D.
    ONCOLOGY RESEARCH AND TREATMENT, 2014, 37 : 233 - 234
  • [42] Efficacy and tolerability of lenalidomide (LEN) in patients (pts) 75 and older versus those younger than 75 with RBC transfusion-dependent low/int-1-risk MDS and del 5q
    Fenaux, Pierre
    Guerci-Bresler, Agnes
    Muus, Petra
    Sekeres, Mikkael A.
    Giagounidis, Aristoteles
    Deeg, H. Joachim
    Greenberg, Peter
    Skikne, Barry
    Yu, Xujie
    List, Alan F.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [43] Disease progression in del(5q) MDS patients treated with lenalidomide: Analysis of risk factors and long term outcome in 45 patients
    Giagounidis, A.
    Haase, S.
    Lohrbacher, V.
    Schuran, B.
    Heinsch, M.
    Aul, C.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 85 - 85
  • [44] A G polymorphism in the CRBN gene acts as a biomarker of response to treatment with lenalidomide in low/int-1 risk MDS without del(5q)
    Sardnal, V.
    Rouquette, A.
    Kaltenbach, S.
    Bally, C.
    Chesnais, V.
    Leschi, C.
    Ades, L.
    Santini, V.
    Park, S.
    Toma, A.
    Fenaux, P.
    Dreyfus, F.
    Fontenay, M.
    Kosmider, O.
    LEUKEMIA, 2013, 27 (07) : 1610 - 1613
  • [45] A G polymorphism in the CRBN gene acts as a biomarker of response to treatment with lenalidomide in low/int-1 risk MDS without del(5q)
    V Sardnal
    A Rouquette
    S Kaltenbach
    C Bally
    V Chesnais
    C Leschi
    L Ades
    V Santini
    S Park
    A Toma
    P Fenaux
    F Dreyfus
    M Fontenay
    O Kosmider
    Leukemia, 2013, 27 : 1610 - 1613
  • [46] Lenalidomide does not increase AML progression risk in RBC transfusion-dependent patients with Low- or Intermediate-1-risk MDS with del(5q): a comparative analysis
    A Kuendgen
    M Lauseker
    A F List
    P Fenaux
    A A Giagounidis
    N A Brandenburg
    J Backstrom
    A Glasmacher
    J Hasford
    U Germing
    Leukemia, 2013, 27 : 1072 - 1079
  • [47] Lenalidomide does not increase AML progression risk in RBC transfusion-dependent patients with Low- or Intermediate-1-risk MDS with del(5q): a comparative analysis
    Kuendgen, A.
    Lauseker, M.
    List, A. F.
    Fenaux, P.
    Giagounidis, A. A.
    Brandenburg, N. A.
    Backstrom, J.
    Glasmacher, A.
    Hasford, J.
    Germing, U.
    LEUKEMIA, 2013, 27 (05) : 1072 - 1079
  • [48] Disease progression in del(5q) MDS patients treated with lenalidomide: analysis of risk factors and long-term outcome in 44 patients
    Giagounidis, A. A. N.
    Haase, S.
    Lohrbacher, V.
    Heinsch, M.
    Schuran, B.
    Aul, C.
    LEUKEMIA RESEARCH, 2007, 31 : S120 - S121
  • [49] CLINICAL FACTORS PREDISPOSING TO ACHIEVEMENT OF RBC TRANSFUSION INDEPENDENCEIN LENALIDOMIDE-TREATED PATIENTS WITH LOW/INTERMEDIATE-1-RISK MYELODYSPLASTIC SYNDROMES) WITHOUT DEL(5q) IN MDS-005 STUDY
    Santini, V.
    Li, J. Shiansong
    Swern, A. S.
    Almeida, A.
    Giagounidis, A.
    Fu, T.
    Sanna, A.
    Hoenekopp, A.
    Beach, C. L.
    Skikne, B.
    Fenaux, P.
    HAEMATOLOGICA, 2015, 100 : 3 - 4
  • [50] Early lenalidomide (LEN) dose intensity and durable RBC-transfusion independence (RBC-TI) in patients (pts) with low-/int-1-risk myelodysplastic syndromes (MDS) and del5q
    List, A. F.
    Giagounidis, A.
    Backstrom, J. T.
    Fu, T.
    Fenaux, P.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
12345